Agent
Lepodisiran (LY3819469)
Status Phase 3 outcomes (ACCLAIM-Lp(a), n=17,300, enrolment complete)
An extended-duration GalNAc siRNA against LPA: a single 608 mg dose kept Lp(a) 94 percent down at day 337 (JAMA 2023) and 400 mg twice a year lowered time-averaged Lp(a) by about 94 percent in ALPACA (NEJM 2025). ACCLAIM-Lp(a), the largest Lp(a) outcomes trial, has finished enrolling and runs to 2029; dosing is about every six months.
Milestones. Phase 1 (Nissen, JAMA 2023, AHA 2023); ALPACA (Nissen, NEJM 2025, ACC.25); ACCLAIM-Lp(a) started March 2024; coronary plaque study NCT07613294 started June 2026.
lepodisiranRNA therapeuticssiRNA
Page updated 17 August 2026.